Molnupiravir: mutagenic, carcinogenic, authorized in the UK

Goldstein, L., TrialSite News

Nov 2021

Source PDF All Studies Meta AnalysisMeta

Discussion of concerns with molnupiravir and the MOVe-OUT trial. Author notes that results showing bone marrow toxicity in dogs were mentioned in this preprint1, but removed from the journal version2. Some additional details were provided by the UK regulator:

“Reversible, dose-related bone marrow toxicity affecting all haematopoietic cell lines was observed in dogs at ≥17 mg/kg/day (0.4 times the human NHC exposure at the recommended human dose (RHD)).”3

This article can also be found at4.

Reviews covering molnupiravir for COVID-19 include5-13.

Important missing comments or errors? Let us know.

1. medrxiv.org, www.medrxiv.org/content/10.1101/2020.12.10.20235747v1.www.medrxiv.org/content/10.1101/2020.12.10.20235747v1.

2. journals.asm.org, journals.asm.org/doi/full/10.1128/AAC.02428-20.journals.asm.org/doi/full/10.1128/AAC.02428-20.

3. gov.uk, www.gov.uk/government/publications/regulatory-approval-of-lagevrio-molnupiravir/summary-of-product-characteristics-for-lagevrio.www.gov.uk/government/publications/regulatory-approval-of-lagevrio-molnupiravir/summary-of-product-characteristics-for-lagevrio.

4. defyccc.com, defyccc.com/wp-content/uploads/Molnupiravir-Mutagenic-Carcinogenic-TSN.pdf.defyccc.com/wp-content/uploads/Molnupiravir-Mutagenic-Carcinogenic-TSN.pdf.

5. Bacigalupo et al., Unveiling patenting strategies of therapeutics and vaccines: evergreening in the context of COVID-19 pandemic, Frontiers in Medicine, doi:10.3389/fmed.2023.1287542.frontiersin.org, doi.org.

6. Kosakovsky Pond et al., Anti-COVID drug accelerates viral evolution, Nature, doi:10.1038/d41586-023-03248-3.nature.com, doi.org.

7. Boretti, A., On the choice of Molnupiravir and Paxlovid as the only antivirals permitted for COVID-19 infection in Australia, Clinical and Experimental Medicine, doi:10.1007/s10238-023-01010-7.springer.com, doi.org.

8. Hadj Hassine et al., Lethal Mutagenesis of RNA Viruses and Approved Drugs with Antiviral Mutagenic Activity, Viruses, doi:10.3390/v14040841.mdpi.com, doi.org.

9. Swanstrom et al., Lethal mutagenesis as an antiviral strategy, Science, doi:10.1126/science.abn0048.science.org, doi.org.

10. Waters et al., Human genetic risk of treatment with antiviral nucleoside analog drugs that induce lethal mutagenesis: the special case of molnupiravir, Environmental and Molecular Mutagenesis, doi:10.1002/em.22471.wiley.com, doi.org.

11. Anonymous, Treating a Pandemic Respiratory Disease with a Mutagen is a Doomsday Scenario, Authorea, doi:10.22541/au.163854323.34557301/v1.authorea.com, doi.org.

12. Goldstein, L., Molnupiravir: mutagenic, carcinogenic, authorized in the UK, TrialSite News, trialsitenews.com/molnupiravir-mutagenic-carcinogenic-authorized-in-the-uk/.trialsitenews.com.

13. Malone et al., Molnupiravir: coding for catastrophe, Nature Structural & Molecular Biology, doi:10.1038/s41594-021-00657-8.nature.com, doi.org.

Goldstein et al., 6 Nov 2021, preprint, 1 author.

This Paper Molnupiravir All

Download Image

Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.

Submit

Post

@CovidAnalysis

FAQ

Public domain CC0 1.0